Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial (PRROTECT)

Official Title: Phase 2 Study of Omalizumab in Oral Peanut Desensitization (PRROTECT)

The investigators will perform a double blind, placebo controlled clinical trial with Xolair (omalizumab) at four centers to safely and rapidly desensitize patients with severe peanut allergy. The investigators will determine if pretreatment with anti-IgE mAb (Xolair/omalizumab) can greatly reduce allergic reactions and allow for faster and safer desensitization

NCT01781637
Pongracic, Jacqueline A., MD
Interventional
No

Contact Information:

Jacqueline Pongracic, MD

Principal Investigator

888-573-1833